The understanding of the pharmacokinetics and pharmacodynamics of the fluoroquinolone class of antimicrobial agents has progressed dramatically in the past 5 years or so. However, this is still a work-in-progress, and there is not a consensus on how such parameters might be applied to improve antimicrobial therapy in patients at the present time. In their paper, Schentag et al. 1 discuss several limitations of animal model research. They acknowledge that pharmacodynamic studies of organisms with defined resistance mechanisms are few. Most animal studies were conducted using fluoroquinolone-susceptible bacterial strains and inocula of 10 6 to 10 7 cfu/mL. The genetic composition of the starting populations was not determined. The probability that resistant variants were present in the initial populations depends on the mutation rate for the fluoroquinolone and the size of the starting population. Since spontaneous mutations resulting in decreased fluoroquinolone susceptibility arise at low frequency (10 -6 to 10 -8 ), it is possible that resistant variants were not present in the starting populations in some studies. This may explain the discrepancy in maximum concentration/minimum inhibitory concentration (MIC) and area under the inhibitory concentration curve (AUIC) break points between studies since lower fluoroquinolone concentrations (and hence lower pharmacodynamic break point values) may have been identified in studies using inocula that lacked resistant variants. Low inoculum sizes could also have focused the resistance analyses on non-topoisomerase mutants (e.g., efflux variants) possessing only modest decreases in fluoroquinolone susceptibility.
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Non-topoisomerase-resistant variants appear more frequently from wild-type populations than do topoisomerase mutants. Thus, even in animal studies where resistant variants were present in inocula, the relevance of the pharmacodynamic break points to resistance is questionable because the populations studied still may not have been large enough to ensure the presence of topoisomerase mutants that are associated with higher levels of fluoroquinolone resistance.
If one assumes that the key to successful fluoroquinolone therapy is to eradicate the small numbers of topoisomerase mutants that may be present in bacterial populations, it may make more sense to design future animal studies to evaluate the killing activity of fluoroquinolones against topoisomerase mutants. Because topoisomerase mutants have not been extensively evaluated in animal models, it is uncertain whether the fluoroquinolone killing rates for mutants are similar to those for wild-type bacteria at comparable AUIC exposures. In vitro time-kill studies have demonstrated different killing rates for different fluoroquinolones (at comparable exposures relative to the MIC) against topoisomerase (grA) mutants of Staphylococcus aureus. If these findings are corroborated in in vitro model and animal studies, they would argue against a universal fluoroquinolone AUIC break point for S. aureus. 2 At this time, we are not sure what the most appropriate length of therapy in animal models might be to determine rates of antimicrobial resistance. We suspect, however, that most animal models are run over a relatively short period of 24 to 48 hours; therefore, the duration of several animal studies may have been insufficient to assess the emergence of resistance. Topoisomerase mutant derivatives of some bacterial species have been found to possess decreased net growth rates compared with their wild-type parents. The decreased growth rates of topoisomerase mutants are consistent with the notion that antimicrobial resistance imposes a biological cost on bacterial fitness. In other words, when you have resistance, it sometimes comes at a cost, and that cost is often a decrease in the bacterial growth rate. Thus, the AUIC break points identified in studies of insufficient duration may have been falsely low since these studies may not have allowed adequate time for the appearance of topoisomerase mutants. [2] [3] [4] [5] [6] [7] Several experiments may have been of insufficient duration to allow for the emergence of resistant variants since their appearance may be delayed if there was a fitness cost associated with resistance. Mathematical modeling also suggests that the size of susceptible and resistant populations employed in fluoroquinolone pharmacodynamic studies may have influenced the emergence of resistance. 8, 9 Spontaneous and adaptive mutation rates for different fluoroquinolones may exhibit different spontaneous and adaptive mutation rates, which further complicates interpretation of these studies. 9 Schentag et al. have undertaken the difficult task of attempting to review diverse studies with different designs and derive meaningful pharmacodynamic relationships from them. Their article highlights the importance of developing a consensus for conducting pharmacodynamic studies of antimicrobial resistance. With consistent standards, data from different studies might be pooled, enhancing their usefulness. The recent standardization of pharmacodynamic terminology for antimicrobial agents is a promising step in that direction. 10 Schentag et al. have in the past published reviews on fluoroquinolones. One of their articles discusses animal models and AUICs. 11 An AUIC of 250 was mentioned, but what also was discussed was the fact that an AUIC >250 did not increase the rate of bacterial eradication. For our purposes, until better data are established, we will continue to believe that for gram-positive bacteria, in particular, Streptococcus pneumoniae, both clinical and in vitro models suggest an AUIC of 30-35 is sufficient to cure most infections. 12 For gram-negative bacteria, an AUIC of 100 -125 seems sufficient. We are simply not ready to call for an AUIC of ≥250.
In order for clinical microbiology laboratories to alter the way they report fluoroquinolone susceptibilities, the National Committee on Clinical Laboratory Standards would have to develop and approve a completely new approach, which would take 3-5 years at a minimum. We believe the day the clinical microbiology laboratory reports the AUIC instead of and MIC is therefore at least 5 years down the road.
